EGFR and medullary thyroid gland carcinoma: Vandetanib is an oral multi-TKI that inhibits RET, EGFR (Epidermal Growth Factor Receptor), and VEGFR-2/3, and is approved for the treatment of medullary thyroid carcinoma [46].